173 related articles for article (PubMed ID: 2245488)
41. Novel galactosylated liposomes for hepatocyte-selective targeting of lipophilic drugs.
Kawakami S; Munakata C; Fumoto S; Yamashita F; Hashida M
J Pharm Sci; 2001 Feb; 90(2):105-13. PubMed ID: 11169527
[TBL] [Abstract][Full Text] [Related]
42. Carboplatin-liposomes (CPL) in immunodeficient mice: improved antitumor activity for breast carcinomas and stimulation of hematopoiesis.
Fichtner I; Reszka R; Goan SR; Naundorf H
Med Oncol; 1994; 11(3-4):111-9. PubMed ID: 7633830
[TBL] [Abstract][Full Text] [Related]
43. Liposomal drug delivery in an in vitro 3D bone marrow model for multiple myeloma.
Braham MV; Deshantri AK; Minnema MC; Öner FC; Schiffelers RM; Fens MH; Alblas J
Int J Nanomedicine; 2018; 13():8105-8118. PubMed ID: 30555229
[TBL] [Abstract][Full Text] [Related]
44. Optimized thermosensitive liposomes for selective doxorubicin delivery: formulation development, quality analysis and bioactivity proof.
Levacheva I; Samsonova O; Tazina E; Beck-Broichsitter M; Levachev S; Strehlow B; Baryshnikova M; Oborotova N; Baryshnikov A; Bakowsky U
Colloids Surf B Biointerfaces; 2014 Sep; 121():248-56. PubMed ID: 25001189
[TBL] [Abstract][Full Text] [Related]
45. Vascular targeting of doxorubicin using cationic liposomes.
Wu J; Lee A; Lu Y; Lee RJ
Int J Pharm; 2007 Jun; 337(1-2):329-35. PubMed ID: 17275230
[TBL] [Abstract][Full Text] [Related]
46. Controlled biodistribution of galactosylated liposomes and incorporated probucol in hepatocyte-selective drug targeting.
Hattori Y; Kawakami S; Yamashita F; Hashida M
J Control Release; 2000 Dec; 69(3):369-77. PubMed ID: 11102677
[TBL] [Abstract][Full Text] [Related]
47. Anti-CD19-targeted liposomal doxorubicin improves the therapeutic efficacy in murine B-cell lymphoma and ameliorates the toxicity of liposomes with varying drug release rates.
Allen TM; Mumbengegwi DR; Charrois GJ
Clin Cancer Res; 2005 May; 11(9):3567-73. PubMed ID: 15867261
[TBL] [Abstract][Full Text] [Related]
48. Pre- and postirradiation hemopoietic effects of liposomal muramyl tripeptide phosphatidylethanolamine (MTP-PE) administered to C57Bl/6 mice before irradiation.
Macková NO; Fedorocko P
Neoplasma; 1993; 40(6):379-85. PubMed ID: 8289971
[TBL] [Abstract][Full Text] [Related]
49. Liposomal encapsulation of azidothymidine results in decreased hematopoietic toxicity and enhanced activity against murine acquired immunodeficiency syndrome.
Phillips NC; Tsoukas C
Blood; 1992 Mar; 79(5):1137-43. PubMed ID: 1371411
[TBL] [Abstract][Full Text] [Related]
50. Preclinical pharmacology, toxicology and efficacy of sphingomyelin/cholesterol liposomal vincristine for therapeutic treatment of cancer.
Webb MS; Logan P; Kanter PM; St-Onge G; Gelmon K; Harasym T; Mayer LD; Bally MB
Cancer Chemother Pharmacol; 1998; 42(6):461-70. PubMed ID: 9788572
[TBL] [Abstract][Full Text] [Related]
51. Preclinical toxicity of liposome-incorporated annamycin: selective bone marrow toxicity with lack of cardiotoxicity.
Zou Y; Priebe W; Stephens LC; Perez-Soler R
Clin Cancer Res; 1995 Nov; 1(11):1369-74. PubMed ID: 9815933
[TBL] [Abstract][Full Text] [Related]
52. Immunotoxicity of multiple dosing regimens of free doxorubicin and doxorubicin entrapped in cardiolipin liposomes.
Rahman A; Joher A; Neefe JR
Br J Cancer; 1986 Sep; 54(3):401-8. PubMed ID: 3489480
[TBL] [Abstract][Full Text] [Related]
53. Antitumor activity of doxorubicin encapsulated in poly(ethylene glycol)-coated liposomes.
Hosoda J; Unezaki S; Maruyama K; Tsuchiya S; Iwatsuru M
Biol Pharm Bull; 1995 Sep; 18(9):1234-7. PubMed ID: 8845812
[TBL] [Abstract][Full Text] [Related]
54. Is control of distribution of liposomes between tumors and bone marrow possible?
Nagayasu A; Uchiyama K; Nishida T; Yamagiwa Y; Kawai Y; Kiwada H
Biochim Biophys Acta; 1996 Jan; 1278(1):29-34. PubMed ID: 8611603
[TBL] [Abstract][Full Text] [Related]
55. Direct comparison of liposomal doxorubicin with or without polyethylene glycol coating in C-26 tumor-bearing mice: is surface coating with polyethylene glycol beneficial?
Hong RL; Huang CJ; Tseng YL; Pang VF; Chen ST; Liu JJ; Chang FH
Clin Cancer Res; 1999 Nov; 5(11):3645-52. PubMed ID: 10589782
[TBL] [Abstract][Full Text] [Related]
56. [Cationic liposomes loaded with doxorubicin targeting to the tumor neovasculature in vitro].
Zhao W; Ma HL; Qi XR
Yao Xue Xue Bao; 2007 Sep; 42(9):982-8. PubMed ID: 18050743
[TBL] [Abstract][Full Text] [Related]
57. Engineered breast tumor targeting peptide ligand modified liposomal doxorubicin and the effect of peptide density on anticancer activity.
Shahin M; Soudy R; Aliabadi HM; Kneteman N; Kaur K; Lavasanifar A
Biomaterials; 2013 May; 34(16):4089-4097. PubMed ID: 23465829
[TBL] [Abstract][Full Text] [Related]
58. A simple passive equilibration method for loading carboplatin into pre-formed liposomes incubated with ethanol as a temperature dependent permeability enhancer.
Wehbe M; Malhotra A; Anantha M; Roosendaal J; Leung AWY; Plackett D; Edwards K; Gilabert-Oriol R; Bally MB
J Control Release; 2017 Apr; 252():50-61. PubMed ID: 28286316
[TBL] [Abstract][Full Text] [Related]
59. Doxorubicin-induced chronic cardiotoxicity and its protection by liposomal administration.
Rahman A; More N; Schein PS
Cancer Res; 1982 May; 42(5):1817-25. PubMed ID: 7066898
[TBL] [Abstract][Full Text] [Related]
60. Targeted delivery of doxorubicin via estrone-appended liposomes.
Rai S; Paliwal R; Vaidya B; Khatri K; Goyal AK; Gupta PN; Vyas SP
J Drug Target; 2008 Jul; 16(6):455-63. PubMed ID: 18604658
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
